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Streptococcus pneumoniae is a common bacterium that is 
present in the nasopharynx of many children and some adults, 
where it causes no harm to its carrier but can be transmitted 
to others. If it moves beyond the nasopharynx, however, it can 
cause ear infections or invasive disease, such as pneumonia or 
meningitis. Invasive disease from this organism occurs especially 
in children, the elderly, and individuals with weakened immune 
systems. 
The protective effect of antibodies against bacterial 
pneumonia has been appreciated since the 1930s, when it 
was shown that serum therapy—the transfer of serum from 
an immunized animal to a patient with acute disease caused 
by the same bacterial strain—could reduce mortality from 
pneumococcal pneumonia by half. Subsequent development of 
vaccines based on the bacterium’s polysaccharide capsule, which 
could protect against infection, conﬁ  rmed that an endogenous 
antibody response can provide protection against invasive 
disease. 
One challenge for vaccine development has been the 
existence of many different serotypes (the same species of 
bacteria but with different composition of the polysaccharide 
capsule). As protection usually doesn’t extend to different 
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Tyrosine kinases regulate signaling 
pathways that control cell growth, 
proliferation, motility, and other critical 
cellular processes. Mutations in tyrosine 
kinase genes can lead to abnormal 
kinase activity, and some tumors become 
dependent upon this activity for growth 
and survival. Thus, kinases are attractive 
targets for anti-cancer drugs. Examples 
of new kinase inhibitors include geﬁ  tinib 
and erlotinib, which have recently shown 
promise in treating non-small-cell lung 
cancer. Unfortunately, geﬁ  tinib and 
erlotinib work only in a subset of patients, 
and they can have severe side effects, 
albeit infrequently. So researchers have 
been trying to ﬁ  nd ways to predict who 
will beneﬁ  t from therapy with these 
drugs and who won’t. 
Following the work of Lynch et al. (N 
Engl J Med 350: 2129–2139) and Paez 
et al. (Science 304: 1497–1500), William 
Pao and colleagues have previously 
shown that the epidermal growth factor 
receptor (EGFR), a tyrosine kinase, is 
often mutated in non-small-cell lung 
cancers, and that tumors that harbor such 
mutations are sensitive to geﬁ  tinib and 
erlotinib. 
In this new study, they focused on a 
signaling protein called KRAS, which 
functions downstream of many tyrosine 
kinases, including EGFR. The KRAS gene 
is also often mutated in lung cancers, 
but very few cancers have mutations in 
both EGFR and the KRAS gene. To ﬁ  nd 
out whether KRAS mutations could help 
to predict which patients would respond 
to geﬁ  tinib or erlotinib, the researchers 
looked for mutations in EGFR and KRAS 
genes in 60 tumors for which sensitivity 
to either drug was known. 
They extended their earlier ﬁ  ndings 
that EGFR mutations (which were found 
in 17 of the tumors) were associated with 
sensitivity to the kinase inhibitors, and 
found that tumors that had mutations in 
KRAS (a total of nine) were refractory (i.e., 
did not respond) to either drug. 
These results need to be validated 
in larger and prospective trials that 
use standardized mutation detection 
techniques. If they are conﬁ  rmed, 
knowing the mutation status of EGFR and 
KRAS in tumors could help physicians 
decide which patients should receive 
geﬁ  tinib and/or erlotinib. As Inoue 
and Nukiwa state in a Perspective that 
accompanies the article, “By combining 
all the factors that relate to response or 
resistance, patients who will beneﬁ  t from 
treatment can hopefully be identiﬁ  ed. 
Undoubtedly we have taken a great step 
forward in molecular therapy for lung 
cancer treatment.”
Pao W, Wang TY, Riely GJ, Miller VA, Pan 
Q, et al. (2005) KRAS mutations and primary 
resistance of lung adenocarcinomas to 
geﬁ  tinib or erlotinib. DOI: 10.1371/journal.
pmed.0020017
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Assessing lung tumors for gene mutations 
could help guide therapy
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Parallel age-incidence curves for pneumococcal serotypes suggest a 
common mechanism of protection
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serotypes, vaccination with capsule components from different 
serotypes is necessary to ensure broad protection. Such 
vaccines have been shown to be efﬁ  cient and safe. They are now 
recommended in many countries for infants and toddlers, and for 
people over 65—the two age groups in which invasive disease 
is most common—and for others who are at increased risk of 
pneumococcal disease (e.g., patients with heart, kidney, liver, or 
lung disease, or who have had a splenectomy).
Even without vaccination, however, most exposed individuals 
will never get invasive disease. Instead, they develop natural 
immunity against the different serotypes, though this immunity 
gradually declines with old age. Marc Lipsitch and colleagues 
wanted to understand the immunological basis of this natural 
immunity, and speciﬁ  cally whether it was due to anticapsular 
antibodies. 
If protection from invasive disease is due to acquiring 
anticapsular antibodies against each of the pneumococcal 
serotypes, they argued, this would lead to two predictions about 
the age distribution of disease caused by the different serotypes 
in the non-vaccinated population. First, for serotypes that are 
more common and therefore encountered earlier in life, children 
should develop immunity more quickly, causing disease from 
these types to drop off earlier in life than disease from the less 
common types. Second, protection against invasive disease 
from a particular serotype should coincide with the acquisition 
of antibodies against that serotype, on both the individual and 
population level. 
Neither prediction was borne out by the actual data 
the researchers analyzed, suggesting that there is more to 
natural immunity against pneumococcal disease than just 
anticapsular antibodies. The study doesn’t demonstrate what 
the additional components are, but additional research might 
not just teach us about our immune system but also provide 
clues for further vaccine development. As the authors say, 
“A better understanding of the mechanisms that underlie 
natural immunity to pneumococcus could pave the way for the 
development of more effective, species-speciﬁ  c pneumococcal 
vaccines.”
Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, et al. (2005) 
Are anticapsular antibodies the primary mechanism of protection 
against invasive pneumococcal disease? DOI: 10.1371/journal.
pmed.0020015
Many different things combine to 
cause epidemics of disease. Among 
these factors are the characteristics of 
the infecting organism, the resistance of 
the host, and, as is increasingly realized, 
climatic conditions. 
El Niño, the best known 
climatic disturbance, is caused 
by a warming of the Paciﬁ  c 
Ocean, which then affects 
the climate globally. Previous 
work has suggested that this 
recurring phenomenon can 
have a profound effect on the 
incidence of many diseases, 
including dengue, malaria, and 
diarrheal diseases. 
In a paper in this month’s 
PLoS Medicine, Sultan and 
colleagues from a climate 
research institute and an 
infectious diseases center 
in France looked at the 
relation between climate and 
meningitis outbreaks in Mali 
in West Africa, a region that 
every year between February 
and May sees devastating 
epidemics of meningococcal 
meningitis affecting up to 200,000 
people. The most important recurring 
climatic event in this region is a dry wind, 
known as the Harmattan, that blows 
throughout the winter, causing a drop 
in humidity and the production of vast 
quantities of dust.
What the authors found was that over 
the years 1994–2002, the week of the 
onset of the yearly meningitis epidemic 
came at around the same time as the 
peak of one measure of the wind—the 
sixth week of the year. As Pascual and 
Dobson say in their Perspective article 
on this study, “Sultan and colleagues’ 
study is exceptional in that it illustrates 
a clear relationship between an external 
environmental variable and the initiation 
of disease outbreaks.”
How do climatic changes inﬂ  uence 
disease? In some cases, such as the role 
of ﬂ  ooding in spreading a waterborne 
disease, the causes are perhaps obvious, 
but why should a dry wind affect 
disease incidence? Previous works have 
suggested that the climate can work in a 
number of ways, by inﬂ  uencing 
the life cycle of both disease 
vectors and the disease-
causing organism, and, as 
here perhaps, by affecting the 
resistance of the host. Sultan 
and colleagues speculate that 
the drying effects of the wind 
on the mucous membranes 
could increase the chances 
of the organism getting 
established in the human 
host. Whatever the causes, one 
very useful feature of climate 
is that, once the patterns are 
understood, they can often be 
predicted.
A way of predicting these 
meningitis epidemics could be 
enormously useful. Sultan and 
colleagues looked at only a few 
years, but if these ﬁ  ndings are 
conﬁ  rmed over a longer time 
period, they could make preparing for an 
epidemic much more efﬁ  cient.
Sultan B, Labadi K, Guégan JF, Janicot 
S (2005) Climate drives the meningitis 
epidemics onset in West Africa. DOI: 
10.1371/journal.pmed.0020006
Meningitis and Climate in West Africa
DOI: 10.1371/journal.pmed.0020024
January 2005  |  Volume 2  |  Issue 1  |  e20  |  e24
The image has been removed due to copyright restrictions.    
 PLoS Medicine  |  www.plosmedicine.org 0004
The HIV epidemic is continuing to grow, year by year. 
According to the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), in 2004 there were more people living with the virus 
than ever before, and in the same year more people than ever 
before died of it. So, although in the developed world HIV/AIDS 
is a controllable disease, one with which a treated person might 
expect to have a near normal lifespan, in much of the rest of the 
world AIDS is still a death sentence. Despite the fact that the cost 
of AIDS medicine has come down to around $150 per year in 
the developing world—a much lower cost than previously—the 
drugs are still unavailable to the vast majority of patients. What 
is more, every infected person has the chance of infecting many 
others. Although huge sums of money have been poured into 
combating HIV/AIDS—around US$4.7 billion in 2003—UNAIDS 
estimates this amount is less than half of what is required by 
2005, and only a quarter of what will be required by 2007, to 
mount a comprehensive response to AIDS in low-income and 
middle-income countries. One of the real dilemmas, therefore, of 
HIV/AIDS policy is deciding whether it is better to concentrate 
resources on prevention of infections or on treatment of infected 
individuals. Each approach has ramiﬁ  cations for the other, as 
shown by the experience in some developed countries, where an 
increase in availability of treatment has been accompanied by an 
increase in risk behavior.
An analysis by Joshua Salomon and colleagues in this month’s 
PLoS Medicine suggests that trying to concentrate on one or 
the other of these alternatives is a false dichotomy, and that not 
integrating the two approaches could have a catastrophic effect 
on the global toll of HIV/AIDS by 2020. In this theoretical paper 
the authors analyze the epidemic in sub-Saharan Africa (where 
three-fourths of deaths from AIDS occur). With no change in 
current levels of prevention and care, it is predicted that there 
will be 3.7 million new HIV infections and 2.6 million adults dying 
of AIDS in this region each year within the next two decades. 
Modeling the HIV Epidemic in Africa
DOI: 10.1371/journal.pmed.0020023
Epidemiological studies suggest 
that statins, a class of cholesterol-
lowering drugs, may lower the risk for 
Alzheimer disease. The mechanism for 
this effect is unclear. Alzheimer disease 
is characterized by accumulation of 
amyloid deposits in the brain. 
These deposits are composed 
of amyloid-beta (Aβ) peptide, 
a protein fragment that is 
cleaved off from the amyloid 
precursor protein APP.  APP 
can be cleaved in two different 
ways. Amyloidogenic (“amyloid 
generating”) cleavage by an 
enzyme called beta-secretase 
yields “sticky” Aβ peptides that 
aggregate to form deposits, 
whereas non-amyloidogenic 
cleavage by alpha-secretases 
generates soluble peptides 
that do not form deposits. 
Studies in animal models 
and cell culture suggest that 
statins might modulate APP 
processing and shift the 
balance toward “healthy” (non-
amyloidogenic) cleavage. 
In their quest to understand 
how statins affect APP processing, Sam 
Gandy and colleagues focused on a 
molecule called ROCK1, a kinase enzyme 
that had recently been implicated in APP 
processing. The theoretical link between 
statins and ROCK1 goes as follows: 
statins inhibit the isoprenoid pathway, 
isoprenoids are regulators of the enzyme 
Rho, and Rho in turn activates ROCK1. 
And while such potential connections 
could be drawn for any number of 
molecules, Gandy and colleagues went 
on to test whether statins exert their 
effect on APP cleavage by interfering 
with the isoprenoid/Rho/ROCK1 pathway. 
Working in mouse neuroblastoma 
cells, they conﬁ  rmed that two different 
statins increased healthy cleavage of 
APP. When they directly interfered with 
the isoprenoid/Rho/ROCK1 pathway 
by adding a drug that inhibits Rho 
activation, they saw effects similar to 
those of the statins (i.e., an increase in 
healthy cleavage). The same effects were 
seen when they transfected the cells 
with a dominant negative form of ROCK1 
(which inactivates the normal ROCK1 
molecules in the cell); this outcome 
shows that the pathway can 
inﬂ  uence APP cleavage. Most 
conclusively, when they added 
a version of ROCK1 that was 
constitutively (always) active, 
they reduced basal levels and 
abolished statin-stimulated 
levels of healthy cleavage. 
Taken together, these results 
suggest that statins inﬂ  uence 
APP processing, at least in part, 
by modulating the isoprenoid 
pathway and inactivating the 
ROCK1 kinase. Future studies 
are necessary to determine 
whether this mechanism is 
actually responsible for the 
apparent clinical beneﬁ  ts 
of statins. Another question 
worth exploring further is 
whether ROCK1 might be a 
suitable target for therapeutic 
interventions that aim to 
decrease harmful, and promote healthy, 
cleavage of APP. 
Pedrini S, Carter TL, Prendergast G, 
Petanceska S, Ehrlich ME, et al. (2005) 
Modulation of statin-activated shedding of 
Alzheimer APP ectodomain by ROCK. DOI: 
10.1371/journal.pmed.0020018
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The authors predicted that concentrating on prevention alone 
could decrease yearly infections by half, and that concentrating 
on treatment could decrease yearly infections by 6%. However, 
combining both approaches could yield substantially greater 
beneﬁ  ts than the sum of the two alone—lowering projected 
new infections by 74% and projected annual mortality by half. 
These percentages translate into 29 million new infections and 
10 million deaths averted between 2004 and 2020.
The challenge now is obviously how to put these policy 
suggestions into practice. The current World Health Organization 
treatment target of having three million people on antiretroviral 
therapy by the end of 2005 (the  “3 by 5” objective) provides a 
yardstick for only one part of the equation. The authors comment 
that the mobilization of communities that will be needed 
to achieve the 3 by 5 objective should also be harnessed for 
prevention, and that those who teach prevention must also be 
allowed to get care for those infected. As the authors say, only by 
doing so “will we at last move from slogans to impact.”
Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, et al. 
(2005) Integrating HIV prevention and treatment: From slogans to 
impact. DOI: 10.1371/journal.pmed.0020016
DOI: 10.1371/journal.pmed.0020023.g001
The best strategy is to combine prevention and treatment 
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